Otsuka Holdings Co. Ltd. said EPS for the first half was ¥117.11, a gain of 50.1% from ¥78.04 in the year-earlier period.

For the six months ended June 30, profit attributable to owners of the company totaled ¥63.88 billion, a gain of 50.6% from ¥42.43 billion in 2017.

Revenue climbed on an annual basis to ¥618.33 billion from ¥595.36 billion, and research and development expenses rose 19.0% year over year to ¥96.08 billion from ¥80.77 billion.

Operating profit totaled ¥78.31 billion compared with ¥49.51 billion a year ago.

The Tokyo-based drugmaker still expects revenue at ¥1.300 trillion for full year 2018. The company also forecasts profit attributable to owners of the company at ¥115.00 billion for the fiscal full year, up from the previous forecast of ¥105.00 billion.

As of Aug. 7, US$1 was equivalent to ¥111.19.